Phase II pilot trial of 'chemo-switch' regimen [vinblastine, cisplatin, interferon alpha, interleukin 2] of biochemotherapy followed by daily low-dose temozolomide plus sorafenib in advanced melanoma

Trial Profile

Phase II pilot trial of 'chemo-switch' regimen [vinblastine, cisplatin, interferon alpha, interleukin 2] of biochemotherapy followed by daily low-dose temozolomide plus sorafenib in advanced melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Interferon alpha; Interleukin-2; Temozolomide; Vinblastine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 31 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top